Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Hematology Am Soc Hematol Educ Program. 2011;2011:384-90. doi: 10.1182/asheducation-2011.1.384.
The recognition of that patients with Immune Thrombocytopenia (ITP) have functional thrombopoietin deficiency and decreased platelet production due to immune-mediated megakaryocytic injury has challenged the traditional view of this disease as predominantly a disorder of antibody-mediated platelet destruction. The therapy of chronic refractory ITP has been transformed by the approval of the thrombopoietin minetics, romiplostim and eltrombopag, which have shown remarkable efficacy in randomized trials. The use of these agents earlier in the disease course after failure of corticosteroid therapy remains controversial. In this article, we review the current data on the efficacy and safety of thrombopoietin receptor agonists and discuss other therapies as well as diagnostic work up of ITP.
免疫性血小板减少症（ITP）患者存在功能性促血小板生成素缺乏和巨核细胞损伤导致的血小板生成减少，这一认识挑战了传统观点，即该病主要是抗体介导的血小板破坏紊乱。促血小板生成素模拟物罗米司亭和艾曲波帕的批准改变了慢性难治性 ITP 的治疗方法，这些药物在随机试验中显示出显著疗效。在皮质类固醇治疗失败后疾病早期使用这些药物仍然存在争议。本文综述了促血小板生成素受体激动剂的疗效和安全性的最新数据，并讨论了其他治疗方法以及 ITP 的诊断。
